? LEADERSHIP, PLANNING AND EVALUATION Raphael Pollock, MD, PhD serves as Director for The Ohio State University Comprehensive Cancer Center (OSUCCC). Dr. Pollock is assisted by a Senior Leadership team of nationally recognized leaders in cancer research, clinical care, and prevention and education includes Peter Shields, MD (Deputy Director); William Carson, MD (Associate Director for Clinical Research); Electra Paskett, PhD (Associate Director for Population Sciences and Community Outreach); Patrick Green, PhD (Associate Director for Basic Science); Claire Verschraegen, MD (Associate Director for Translational Science); Heather Hampel, MS, LGC (Associate Director for Biospecimen Research); Sharyn Baker, PharmD, PhD (Associate Director for Shared Resources); Lawrence Kirschner, MD, PhD (Associate Director for Education and Training); John Byrd, MD (Senior Advisor) and David Gosky, MA, MBA (Executive Director for Administration). This highly experienced Senior Leadership team works together to: ensure consistency in the shared vision and goals of the OSUCCC; foster synergistic and highly collaborative interactions among the basic, population, translational and clinical research components of the OSUCCC; effectively leverage all available resources at OSU, state and national levels; engage in clinical trials, community outreach, education and mentoring; and oversee all activities of the OSUCCC. Continuous planning and evaluation are key to the development and sustained excellence of the OSUCCC, and helps ensure its strong scientific trajectory. Planning and evaluation by the OSUCCC External Scientific and Internal Advisory Boards (ESAB and IAB, respectively), the Associate Directors Committee (ADC), and other councils provide the Director and Senior Leadership ongoing guidance and support. The ESAB is the primary external mechanism for objective review and oversight of the OSUCCC, including its progress in basic, translational, population and community research, and its leadership and strategic direction. The ADC, Program Leaders Committee, Shared Resource Team Leaders Committee, and IAB (composed of OSU deans and associate deans of research) facilitate internal planning and evaluation. The Executive Council is responsible for the cohesive vision of cancer research and clinical programs of the OSUCCC-James and provides another important internal mechanism for planning and evaluation. Dr. Pollock and the Senior Leadership recently created the OSUCCC-James strategic plan for the next five years, building upon existing strong foundations. The overarching goal of the new plan, entitled Ascending to New Heights, is to drive new discoveries that transform cancer care across the continuum of prevention, treatment and survivorship to improve the health of the OSUCCC catchment area communities. Goals supporting research across the lifespan are informed by data about the cancer burden in the catchment area and through bidirectional communication with community advisory boards. Four major research initiatives (immuno-oncology, cancer engineering, translational genomics, and cancer prevention and survivorship) in the plan will accelerate our vision of creating a cancer-free world, one person, one discovery at a time.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090001
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications